ArticleEuropean journal of pediatrics2025
Two-year follow-up on multisystem inflammatory syndrome in children (MIS-c): findings from a tertiary paediatric hospital in Latvia.
Article in European journal of pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Comment on "Two-year follow-up on multisystem inflammatory syndrome in children (MIS-c): findings from a tertiary paediatric hospital in Latvia".European journal of pediatrics · 2025Article
- MIS-C pathogenesis: immune dysregulation & viral triggers.Frontiers in immunology · 2025Review
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to assess long-term recovery from multisystem inflammatory syndrome in children (MIS-c) 24 months after admission. This prospective longitudinal cohort study included 21 children diagnosed with MIS-c according to Centers for Disease Control and Prevention (CDC) criteria and admitted to Children's Clinical University Hospital in Riga. Outpatient follow-up consisted of repeated visits at 3, 6, 12, and 24 months after the acute phase of MIS-c. In addition to the initial interview and physical examination, the patients were asked to perform functional tests (six-minute walking test (6-MWT) and orthostatic intolerance test (OIT)) and complete validated tools (Chalder Fatigue Questionnaire (CFQ-11) and Karolinska Sleep Questionnaire (KSQ)). The median age of the study group was 6 years (IQR, 5.0-10.0 years; range, 1-16 years). The KSQ showed that sleep quality, non-restorative sleep, and daytime sleepiness were more associated with the 1-3-month period than with long-term sequelae. At 1-3 months, all children exhibited physical and psychological fatigue (bi-modal score ≥ 4). By 6 months, no patient showed fatigue (bi-modal score < 3). The OIT showed no signs of orthostatic intolerance, orthostatic hypotension, or POTS among patients. Heart rate and blood pressure changes were mild. The 6-MWT showed significant improvement in walking distance.
conclusionsMost improvements in sleep quality, reduction in fatigue, orthostatic compensation, and aerobic capacity occur within the first 6 months after acute MIS-c, with no long-term sequelae. WHAT IS KNOWN: • Multisystem inflammatory syndrome in children (MIS-c) is a potentially life-threatening complication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. • Data on long-term outcomes of patients with MIS-c are scarce, providing very limited insights into children's well-being after 12 months. WHAT IS NEW: • Our two-year study indicated that for most patients, physical and psychological health improvements occurred within the first 6 months after acute MIS-c, without long-term consequences. • RDW/PLT may serve as a practical early marker of oxidative stress response in neonates, reinforcing the safety of phototherapy while raising questions for preterm care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.